SCHEMBL30101416

SCHEMBL30101416

c1cc2c(c(OCCN3CCOCC3)c1)CNC2

nearest known ligand 0.56

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.53
DRD1 P21728 1/20 0.51
DRD4 P21917 1/20 0.51
DRD5 P21918 1/20 0.51
TIPARP Q7Z3E1 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
POLB P06746 1/20 0.49
KDM4E B2RXH2 3/20 0.48
MAOB P27338 1/20 0.47
TSHR P16473 2/20 0.47
CYP2D6 P10635 1/20 0.47
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL383947 0.94 HRH3 (0.61) HRH3SMN1; SMN2KDM4ETSHRCYP2D6
SCHEMBL21744253 0.89 HRH3 (0.56) HRH3DRD1DRD4DRD5TIPARP
SCHEMBL30101340 0.86 HRH3 (0.69) HRH3DRD1DRD4DRD5TIPARP
SCHEMBL30101386 0.86 HRH3 (0.55) HRH3TIPARPPOLBKDM4E
SCHEMBL30101435 0.86 HRH3 (0.58) HRH3TIPARPPOLBKDM4ETSHR
SCHEMBL30101529 0.79 TIPARP (0.55) HRH3TIPARPKDM4E
SCHEMBL24913864 0.75 CYP2A13 (0.53) HRH3KDM4ECYP2D6
SCHEMBL14641573 0.74 KDM4E (0.48) HRH3SMN1; SMN2KDM4ERAB9A
SCHEMBL14578233 0.74 DRD1 (0.65) DRD1DRD4DRD5SMN1; SMN2POLB
SCHEMBL30101429 0.74 HRH3 (0.46) HRH3TIPARP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS, INC. 2025-01-30 US disclosed
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2023-06-22 US disclosed
US-11566020-B1 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2023-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 HRH3 1405/4885DRD1 4165/4885DRD4 3518/4885
US-11566020-B1 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 HRH3 1405/4885DRD1 4165/4885DRD4 3518/4885
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 HRH3 1405/4885DRD1 4165/4885DRD4 3518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.